Molecular structure of Methylprednisolone, CAS Number: 83-43-2
Methylprednisolone (CAS 83-43-2)
See product citations (1)
Alternate Names:
1,4-pregnadien-6α-methyl-11β, 17, 21-triol-3, 20-dione; Medrate; Medrol; Medrone; Urbason
Application:
Methylprednisolone is an apoptosis inducer
CAS Number:
83-43-2
Molecular Weight:
374.47
Molecular Formula:
C22H30O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Methylprednisolone is a syntheticthat mimics the natural hormone produced by the adrenal glands. It serves as a glucocorticoid and plays a vital role in regulating metabolism and immune system function. Moreover, methylprednisolone finds extensive application in scientific research. In vivo studies employ methylprednisolone in live animals to explore its impact on various biological processes, while in vitro studies involve its utilization in cell cultures to investigate its effects on cellular processes. By binding to the glucocorticoid receptor within the cell nucleus, methylprednisolone initiates a cascade of gene expression regulation.
Methylprednisolone (CAS 83-43-2) References
- Pharmacokinetics of high-dose methylprednisolone in children. | Ito, S., et al. 1992. Dev Pharmacol Ther. 19: 99-105. PMID: 1340442
- Concentration of methylprednisolone in the centrodistal joint after administration of methylprednisolone acetate in the tarsometatarsal joint. | Serena, A., et al. 2005. Equine Vet J. 37: 172-4. PMID: 15779632
- Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass. | Kong, AN., et al. 1990. Pharmacotherapy. 10: 29-34. PMID: 2179900
- Methylprednisolone interventions in myocardial infarction: a controversial subject. | LeGal, YM. and Morrissey, LL. 1990. Can J Cardiol. 6: 405-10. PMID: 2276078
- Cushing's syndrome from epidural methylprednisolone. | Tuel, SM., et al. 1990. Pain. 40: 81-84. PMID: 2339020
- [Methylprednisolone- acute spinal cord injury, benefits or risks?]. | Tęsiorowski, M., et al. 2013. Postepy Hig Med Dosw (Online). 67: 601-9. PMID: 23800640
- Methylprednisolone disposition in rabbits. Analysis, prodrug conversion, reversible metabolism, and comparison with man. | Ebling, WF., et al. 1985. Drug Metab Dispos. 13: 296-304. PMID: 2861987
- Comparative pharmacokinetics of methylprednisolone phosphate and hemisuccinate in high doses. | Möllmann, H., et al. 1988. Pharm Res. 5: 509-13. PMID: 3072558
- Methylprednisolone may be associated with improved lung compliance in acute respiratory distress syndrome patients on veno-venous extracorporeal membrane oxygenation. | Tabatabai, A., et al. 2020. Perfusion. 35: 515-520. PMID: 32072859
- Design, Synthesis, and Renal Targeting of Methylprednisolone-Lysozyme. | Pan, X., et al. 2020. Int J Mol Sci. 21: PMID: 32168938
- Methylprednisolone in acute asthma. | . 1986. N Engl J Med. 314: 1704-6. PMID: 3713774
- Subcutaneous atrophy following methylprednisolone injection in Osgood-Schlatter epiphysitis. | Rostron, PK. and Calver, RF. 1979. J Bone Joint Surg Am. 61: 627-8. PMID: 438257
- Influence of route of administration on the pharmacokinetics of methylprednisolone. | Antal, EJ., et al. 1983. J Pharmacokinet Biopharm. 11: 561-76. PMID: 6678310
- [Methylprednisolone in traumatic spinal cord injuries: not proven to be beneficial to the patient at the present time]. | Vandertop, WP., et al. 1998. Ned Tijdschr Geneeskd. 142: 1061-4. PMID: 9623220
Inhibitor of:
AAT-1, CD22, IDHC, KIR3DL3, Neuronal PAS Domain Protein (NPAS), NPAS2, NPAS4, PRG-3, Tenascin-X, and TREML2.Activator of:
AGP-1, C1orf77, CD2BP2, Cyclophilin G, HIP2, HPV16 E7, HPV16 L2, MCT3, Med18, and OLFML3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Methylprednisolone, 100 mg | sc-205749 | 100 mg | $117.00 | |||
Methylprednisolone, 500 mg | sc-205749A | 500 mg | $265.00 |